Low dose of homoharringtonine and cytarabine-based priming induction regimens for patients with de novo acute myeloid leukemia and high-risk myelodysplastic syndrome aged over 70 years. Issue 1 (1st January 2021)

• Record Type: Journal Article
• Authors: Wang, Fang; Xu, Wenyan; Liu, Li; Ren, Xiuhong; Liu, Pingping; Zheng, Li; Zhang, Hao; Zhang, Songsong; Xu, Yaru; Guo, Zhenxing
• Is Part Of: Hematology. Volume 26:Issue 1(2021)
• Page Start: 1040
• Page End: 1045
• Publication Date: 2021-01-01
• Subjects: Acute myeloid leukemia -- 70 years old -- HHT -- Charlson's comorbidity index -- overall survival; Blood -- Diseases -- Periodicals; Hematology -- Periodicals; Blood -- Transfusion -- Periodicals; 616.15005
• DOI: 10.1080/16078454.2021.2009642
• Languages: English
• ISSNs: 1024-5332

Abstract

ABSTRACT: Objectives: Our objective is to retrospectively analyze the response to low dose of homoharringtonine (HHT) and cytarabine-based priming induction regimens in patients above 70 years with de novo acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). Patients and methods: We retrospectively analyzed these very elderly newly diagnosed patients with AML and high-risk MDS, who received low dose of HHT and cytarabine-based priming induction regimens between March 2006 and September 2019. Results: Of the 24 patients, 11 patients (47.8%) achieved complete remission (CR) and 3 (13%) partial remission, and the overall response rate was 60.9%. The estimated median overall survival (OS) time was 12 months and the 1-year OS rate was 47.8%. Patients without CR and Charlson's Comorbidity Index > 2 may be the two independent prognostic factors. The median OS was significantly higher for patients with CR after induction chemotherapy than those without CR (22.93 vs . 8.5 months, p < .01). Conclusion: Our study provides a hint of the efficacy of low dose of HHT and cytarabine-based priming induction regimens for patients aged over 70 years with de novo AML and high-risk MDS should be further studied.